Last reviewed · How we verify
Al(OH)3
Aluminum hydroxide acts as an adjuvant that enhances immune response by promoting antigen presentation and activating innate immunity.
Aluminum hydroxide acts as an adjuvant that enhances immune response by promoting antigen presentation and activating innate immunity. Used for Vaccine adjuvant in phase 3 vaccine development by Janssen Vaccines & Prevention B.V..
At a glance
| Generic name | Al(OH)3 |
|---|---|
| Sponsor | Janssen Vaccines & Prevention B.V. |
| Drug class | Vaccine adjuvant |
| Target | NLRP3 inflammasome; antigen-presenting cells |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Aluminum hydroxide is a widely used vaccine adjuvant that works by creating a depot effect at the injection site, slowing antigen release and enhancing uptake by antigen-presenting cells. It activates the NLRP3 inflammasome and promotes a Th2-biased immune response, increasing antibody production and cellular immunity against the vaccine antigen. This mechanism makes it particularly effective in enhancing humoral immune responses in vaccine formulations.
Approved indications
- Vaccine adjuvant in phase 3 vaccine development by Janssen Vaccines & Prevention B.V.
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults (PHASE1, PHASE2)
- Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (PHASE1, PHASE2)
- Dose-finding Study for AdimrSC-2f Vaccine (PHASE1, PHASE2)
- Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults (PHASE1)
- Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults (PHASE2)
- Orthostatic Hypotension Treatment on Rehab Unit (NA)
- Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults (PHASE2)
- Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |